Otsuka (OTCMKTS:OTSKY) Sees Strong Trading Volume – What’s Next?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw unusually-high trading volume on Wednesday . Approximately 80,392 shares were traded during trading, an increase of 118% from the previous session’s volume of 36,937 shares.The stock last traded at $36.15 and had previously closed at $34.92.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. The Goldman Sachs Group downgraded Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. Morgan Stanley raised Otsuka to an “overweight” rating in a report on Friday, January 23rd. Finally, UBS Group raised Otsuka to a “hold” rating in a report on Tuesday, January 27th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Otsuka presently has a consensus rating of “Hold”.

Otsuka Stock Performance

The stock has a fifty day simple moving average of $34.71 and a two-hundred day simple moving average of $31.49. The stock has a market cap of $39.49 billion and a price-to-earnings ratio of 15.51. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last issued its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.86 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.